IP Verse

Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients - EP3149480

The patent EP3149480 was granted to Amgen on Dec 26, 2018. The application was originally filed on May 20, 2015 under application number EP15727072A. The patent is currently recorded with a legal status of "Revoked".

EP3149480

AMGEN
Application Number
EP15727072A
Filing Date
May 20, 2015
Status
Revoked
Sep 17, 2021
Grant Date
Dec 26, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANOFISep 26, 2019CABINET NONYADMISSIBLE
SANOFISep 26, 2019IPSILONADMISSIBLE

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0623679
DESCRIPTIONWO2004106381
DESCRIPTIONWO2007068354
DESCRIPTIONWO2007131092
DESCRIPTIONWO2008119565
DESCRIPTIONWO2008119566
DESCRIPTIONWO2008119567
DESCRIPTIONWO2010052013
DESCRIPTIONWO2010052014
DESCRIPTIONWO2011051307
DESCRIPTIONWO2012146394
DESCRIPTIONWO9954440
OPPOSITIONWO2011051307
OPPOSITIONWO2012146394
OPPOSITIONWO2014122251

Non-Patent Literature (NPL) Citations (25) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ABBAS H. ABDULSALAM, "Diagnosis of Acute Leukemia in Under-Resourced Laboratories", ABBAS H. ABDULSALAM, Mariastefania Antica, Acute Leukemia - The Scientist's Perspective and Challenge, (20110000), pages 19 - 40, XP055635347-
OPPOSITION- Amgen Research (munich) Gmbh, "Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)", ClinicalTrials.gov, (20111107), URL: https://clinicaltrials.gov/ct2/show/NCT01466179, XP055635360-
OPPOSITION- Amgen Research (Munich) Gmbh, "Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia", ClinicalTrials.gov, (20111116), URL: https://clinicaltrials.gov/ct2/show/NCT01471782, XP055635351-
OPPOSITION- Amgen Research (munich) Gmbh, "Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)", ClinicalTrials.gov, (20100927), URL: https://clinicaltrials.gov/ct2/show/NCT01209286, XP055635357-
OPPOSITION- Anonymous, "Matter of Record (301) 890-4188", Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee, (20121204), pages 1 - 377-
OPPOSITION- Anonymous, "Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee, Notice of meeting", Federal Register, (20120917), vol. 77, no. 180, page 57095, XP055635533-
OPPOSITION- BIANCO et al., "Increased Blasts Mimicking Acute Leukemia in a Patient With Polysubstance Abuse", Arch Pathol Lab Med, (20050200), vol. 129, pages e35 - e38, XP055635326-
OPPOSITION- CONTER et al., "Acute Lymphoblastic Leukemia", Orphanet, (20041200), pages 1 - 13, URL: https://www.orpha.net/data/patho/GB/uk-ALL.pdf, XP055635306-
OPPOSITION- Faramarz Naeim, "Chapter 1 - Structure and Function of Hematopoietic Tissues", Faramarz Naeim, Faramarz Naeim, P. Nagesh Rao and Wayne W. Grody, HEMATOPATHOLOGY, AcademicPress, (20080000), pages 1 - 26, XP055635340-
OPPOSITION- JABBOUR et al., "Central Nervous System Prophylaxis in Adults With Acute Lymphoblastic Leukemia", Cancer, (20100000), vol. 116, no. 10, pages 2290 - 2300, XP055635397-
OPPOSITION- PFEIFER et al., "Risk and Prognosis of Central Nervous System Leukemia in Patients with Philadelphia Chromosome-Positive Acute Leukemias Treated with Imatinib Mesylate", Clinical Cancer Research, (20031015), vol. 9, pages 4674 - 4681, XP055635488-
OPPOSITION- WEINKAUFF et al., "Use of Peripheral Blood Blasts vs Bone Marrow Blasts for Diagnosis of Acute Leukemia", Am J Clin Pathol, (19990000), vol. 111, pages 733 - 740, XP055524636-
OPPOSITION- MARTINEZ-LAPERCHE et al., "Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse", Am. J. Hematol., (20130000), vol. 88, pages 359 - 364, XP055635522
OPPOSITION- AMIN et al., "Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.", Leukemia, (20050000), vol. 19, no. 9, pages 1567 - 1572, XP055397866
OPPOSITION- LAZARUS et al., "Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993", Blood, (20060000), vol. 108, pages 465 - 472, XP055635502
OPPOSITION- BURGER et al., "Diagnostic Cerebrospinal Fluid Examination in Children With Acute Lymphoblastic Leukemia: Significance of Low Leukocyte Counts With Blasts or Traumatic Lumbar Puncture", Journal of Clinical Oncology, (20030115), vol. 21, no. 2, pages 184 - 188, XP055202705
OPPOSITION- CHING-HON PUI, "Toward Optimal Central Nervous System-Directed Treatment in Childhood Acute Lymphoblastic Leukemia", Journal of Clinical Oncology, (20030115), vol. 21, no. 2, pages 179 - 181, XP055635380
OPPOSITION- TOPP et al., "Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival", J Clin Oncol, (20110000), vol. 29, pages 2493 - 2498, XP055112754
OPPOSITION- Robin T. VOLLMER et al., "Blast Counts in Bone Marrow Aspirate Smears: analysis using the poisson probability function, bayes theorem, and information theory.", Am J Clin Pathol, (20090000), vol. 131, no. 2, pages 183 - 188, XP055635315
OPPOSITION- HUPPMANN et al., "Detection of Leukemic Lymphoblasts in CSF is Instrument- Dependent", Am J Clin Pathol, (20120000), vol. 137, no. 5, pages 795 - 799, XP055635302
OPPOSITION- HATHAWAY et al., "Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date", Patient Related Outcome Measures, (20180000), vol. 9, pages 329 - 337, XP055635491
OPPOSITION- DAVIS et al., "Cerebrospinal fluid analysis by flow cytometry in acute lymphoblastic leukemia:is it all that it is cracked up up to be?", Leukemia & Lymphoma, (20140000), vol. 55, no. 7, pages 1441 - 1443, XP055635497
OPPOSITION- JABBOUR et al., "Adult Acute Lymphoblastic Leukemia", Mayo Clin. Proc., (20050000), vol. 80, no. 11, pages 1517 - 1527, XP055635506
OPPOSITION- MAURILLO et al., "Treatment of Acute Myeloid Leukemia with 20-30% Bone Marrow Blasts", Mediterr J Hematol Infect Dis, (20130000), vol. 5, pages 1 - 13, XP055635371
OPPOSITION- CANCELA et al., "Incidence and risk factors for central nervous system relapse in children and adolescents with acute lymphoblastic leukemia", Rev Bras Hematol Hemoter., (20120000), vol. 34, no. 6, pages 436 - 441, XP055635389

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents